<DOC>
	<DOCNO>NCT02039518</DOCNO>
	<brief_summary>The purpose study Evaluate compare safety efficacy Gemcitabine Maintenance Treatment Patients With Extensive SCLC Patients Receiving Etoposide Combined With Platinum Based First-line Chemotherapy</brief_summary>
	<brief_title>Study Gemcitabine Maintenance Treatment Patients With Extensive SCLC Patients</brief_title>
	<detailed_description>first cycle treatment ( day one ) two month last cycle</detailed_description>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . ≥18 year 2 . PS=0,1,2 3 . Patients diagnose histologic , cytologic diagnosis extensive small cell lung cancer 4 . Patients receive Etoposide combine platinum base firstline chemotherapy 6 cycle evidence show patent PR/CR/SD 5 . Expected lifetime &gt; 12 week 6 . Signed write informed consent Small cell lung cancer non small cell hybrid Women pregnancy lactation previously treat two two kind treatment Any non remission &gt; CTCAE cause tumor treatment past grade 2 toxicity Ccr &lt; 30 ml/min ( calculate CockcroftGault formula ) hepatic insufficiency： 1 . Tbil &gt; 1.5×ULN 2 . ALT AST &gt; 2.5×ULN ( Patients liver metastasis &gt; 5×ULN ) Alkaline phosphatase＞2.5 ×ULN ( Patients liver metastasis &gt; 5×ULN ) 3 . Severe symptomatic heart disease 4 . Symptomatic brain metastasis 5 . In last 5 year suffer histological type malignant tumor 6 . There serious uncontrolled systemic disease 7 . During study period plan radiotherapy target lesion 8 . During study period , plan use antineoplastic therapy 9 . Clinical study treatment 30 day begin period prior participate study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Progression free Survival</keyword>
</DOC>